Anticoagulation or Antiplatelet Therapy for Device-Detected Atrial Fibrillation
NEJM 392:1749-1751, Gorey,S., 2025
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke
NEJM 384:2081-2091,2154, Whitlock, R.P.,et al, 2021
Anticoagulation after Ablation for Atrial Fibrillation
NEJM 385:466-468, Kadire, S.R., 2021
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Should Patients with Ischemic Stroke or Transient Ischemic Attack with Atrial Fibrillation and Microbleeds be Anticoagulated?
Stroke 48:3408-3412, Shoamanesh, A.,et al, 2017
Embolic Stroke, Atrial Fibrillation, and Microbleeds
Stroke 47:904-907, Diener, H-C.,et al, 2016
Should Atrial Fibrillation Patients with only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?
Stroke 47:1831-1836, Fauchier, L.,et al, 2016
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
NEJM 373:823-833, Douketis,J.D.,et al, 2015
Association of Cerebral Microbleeds with Mortality in Stroke Patients Having Atrial Fibrillation
Neurol 83:1308-1315,1304, Song, T.J.,et al, 2014
Stroke Patients with Suspected Atrial Fibrillation Should be Started on Anticoagulation Pending the Results of Long-Term Cardiac Monitoring
Stroke 44:298-299,302, Diener, H., 2013
Stroke Patients with Suspected Atrial Fibrillation Should NOT be Started on Anticoagulation WHILE AWAITING the Results of Long-Term Cardiac Monitoring
Stroke 44:300-301,302, Katsnelson, M. & Sacco, R., 2013
Left Atrial Catheter Ablation and Ischemic Stroke
Stroke 43:265-270, Haeusler, K.G.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Resumption of Oral Anticoagulation After Warfarin-Associated Intracerebral Hemorrhage
Stroke 42:3661-3662, 3665, Steiner, T., 2011
Resumption of Oral Anticoagulation After Warfarin-Associated Intracereral Hemorrhage
Stroke 42:3663-3664, 3665, Schulman, S., 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Optimal Timing of Resumption of Warfarin After Intracranial Hemorrhage
Stroke 41:2860-2866, Majeed,A.,et al, 2010
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? Yes
Stroke 40:1942-1943,1946, Furlan,A.J., 2009
Managing the Anticoagulated Patient with Atrial Fibrillation at High Risk of Stroke Who Needs Coronary Intervention
BMJ 337:1110-1111, Lip,G.Y.H., 2008
Anticoagulation Prior to and After Restoration of Sinus
UpToDate, December, Manning,W.J. &Arnsdorf,W.F., 2008
Antithrombotic and Interventional Treatment Options in Cardioembolic Transient Ischaemic Attack and Ischaemic Stroke
JNNP 78:14-24, McCabe,D.J.H. &Rakhit,R.D., 2007
Central Nervous System Injury Associated with Cardiac Surgery
Lancet 368:694-703, Newman,M.F.,et al, 2006
Immediate Anticoagulation for Acute Stroke in Atrial Fibrillation: Yes
Stroke 37:3052-3053,3056, Chamorro,., 2006
Immediate Angicoagulation for Acute Stroke in Atrial Fibrillation: No
Stroke 37:3054-3055,3056, Sandercock,P., 2006
Risk of Thromboembolic Events After Percutaneous Left Atrial Radiofrequency Ablation of Atrial Fibrillation
Circulation 114:759-765, Oral,H.,et al, 2006
Should a Patient With Primary Intracerebral Haemorrhage Receive Antiplatelet or Anticoagulant Therapy?
BMJ 331:439-442, Wani,M.,et al, 2005
Can Patients be Anticoagulated After Intracerebral Hemorrhage?
Stroke 34:1710-1716, Eckman,M.H.,et al, 2003
Systematic Review of Long Term Anticoagulation or Antiplatelet Treatment in Patients with Non-rheumatic Atrial Fibrillation
BMJ 322:321-326, Taylor,F.C.,et al, 2001
Atrial Fibrillation and Stroke
Stroke 32:803-808, Hart,R.G. &Halperin,J.L., 2001
When Should Heparin be Given to Patients with Atrial Fibrillation-Related Embolic Brain Infarcts?
Arch Neurol 56:1059-1060, Caplan,L.R., 1999
Clinical Characteristics & Mgt of Acute Stroke in Pts with Atrial Fib Admitted to US Univ Hosp
Neurol 48:1598-1604, Albers,G.W.,et al, 1997
Stroke:The Way Things Really Are
Stroke 25:1290-1294, Scheinberg,P., 1994
Cerebral Amyloid Angiopathy-How to Translate Updated Diagnostic Criteria for this Multifaceted Disorder to Clinical Practice?
JAMA Neurol 80:225-226, Biessels,G.J., 2023
Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 384:970-971, , 2021
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Evidence-Based Management of Patent Foramen Ovale in Patients with Ischemic Stroke
JAMA Neurol 75:147-148, Kamel, H., 2018
PFO Closure for Cryptogenic Stroke
NEJM 378:1639-1642, Mi, M.Y.,et al, 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Cardiac Magnetic Resonance Imaging: A New Tool to Identify Cardioaortic Sources in Ischaemic Stroke
JNNP 88:31-37, Yaghi, S.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Clinicopathologic Conference, Oligdendroglioma II/IV with IDH1 R132H mutation and codelation of 1p and 19q
NEJM 375:2381-2389, Case 38-206, 2016
Evidence-Based Guideline: Management of an Unprovoked First Seizure in Adults
Neurol 84:1705-1713, Krumholz, A.,et al, 2015
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
An Index to Identify Stroke-Related vs Incidental Patent Foramen Ovale in Cryptogenic Stroke
Neurol 81:619-625,619, Kent, D.M.,et al, 2013